Testing the Effects of a Text Message Caregiver Support Intervention for Latinos
Eligible age
18–100 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this randomized clinical trial it to test the efficacy of CuidaTEXT, the first Alzheimer's disease and Related Dementias (ADRD) caregiver support intervention to capitalize on text messaging, among Latinos. Researchers will compare those who receive the CuidaTEXT intervention to those who do not receive the intervention to see if CuidaTEXT effects Latino caregiver stressors and their negative consequences . Participants will receive a variety of text messages, from automatic to keyword-drive, regarding ADRD education, social support, self-care, ADRD care management, and behavioral symptoms. Participants will also complete measures regarding depressive symptoms, coping, behavioral symptoms, and preparedness for caregiving.
Sponsor: University of Kansas Medical Center
You may qualify if…
- ✓ Over the age of 18
- ✓ Spanish and English-speaking people who identify as Latino
- ✓ Reports providing hands-on care for a relative who has been given a clinical or research ADRD diagnosis and has an Eight-item Informant Interview to Differentiate Aging and Dementia (AD-8) screening score ≥2, indicating cognitive impairment
- ✓ Has a score of 7 or higher on the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10)
- ✓ Self-reports being able to read and write
- ✓ Owns a cell phone with a flat fee, and uses it at least weekly for texting.
You may not qualify if…
- ✕ Participation in another wellbeing-related clinical trial
- ✕ Cohabitation with another participant in the CuidaTEXT R01 Study
- ✕ Participants who provide care for a person with ADRD already cared for by another participant in the CuidaTEXT R01 study
- ✕ Participant plans to move to another country within seven months
Where it's recruiting
Fairway
Source: ClinicalTrials.gov · NCT06728436 · last updated 2025-12-11